Stakeholders

NEPAD

The New Partnership for African’s Development (NEPAD) is a technical body of the African union with a main objective of facilitating and coordinating Africa’s development agenda. NEPAD’s mandate includes contributing to the attainment of the Pharmaceutical Manufacturing Plan for Africa (PMPA), Agenda 2063, and SDGs (among others).
 
The NEPAD Agency serves in the PAVIA Board. The NEPAD Agency also coordinates the AMRH Programme which is aligned to the PAVIA Project in terms of the goals for access to quality, safe and efficacious medical products.
 
AUDA-NEPAD

The New Partnership for African’s Development (NEPAD) is a technical body of the African union with a main objective of facilitating and coordinating Africa’s development agenda. NEPAD’s mandate includes contributing to the attainment of the Pharmaceutical Manufacturing Plan for Africa (PMPA), Agenda 2063, and SDGs (among others).
 
The NEPAD Agency serves in the PAVIA Board. The NEPAD Agency also coordinates the AMRH Programme which is aligned to the PAVIA Project in terms of the goals for access to quality, safe and efficacious medical products.

 
WHO
The WHO has trained over 200 African regulatory staff and is continuing to build capacity to prevent, detect and respond to substandard and falsified medical products. Representation of the WHO as well as the Uppsala Monitoring Centre and the Collaborating Centre for Advocacy and Training in Pharmacovigilance in Accra, Ghana, will steer our activities and findings. The materials developed during PAVIA will be available through the WHO CCs, including Lareb, both during and after the project.
 
EAC
With support from WHO, the East Africa Community countries are working jointly to share the costs of regulatory work and expedite the approval of life-saving medical products. Recently, they jointly assessed and registered two critical bio therapeutic products for cancer. MSH/SIAPS is supporting the EAC medicines regulatory harmonisation initiative in strengthening PV in EAC partners’ states and will ensure uptake of the PAVIA blueprint in these countries.
 
SADEC
The Southern African Development Community works closely with the African Union, NEPAD and other RECs such as EAC to achieve continental and regional integration. We will support their efforts by developing policy briefs about PV activities within PAVIA and will launch the practical blueprint on PV through their networks
 
ISoP
ASoP and ISoP: The African Society of Pharmacovigilance is a chapter of the International Society of Pharmacovigilance, with the goal is to foster the growth of PV in Africa and to include all stakeholders from both public and private sectors. ISoP/ASoP is therefore an important forum to discuss the results and directions of PAVIA.
 
UMC
Uppsala Monitoring Centre (UMC) is an independent, non-profit foundation and a centre for international service and scientific research. We are dedicated to promoting safer use of medicines for patients everywhere, using the science of pharmacovigilance to explore and understand the risks and benefits of medicines.

UMC was established in Uppsala, Sweden in 1978 as the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. UMC operates the technical and scientific aspects of the WHO’s worldwide pharmacovigilance network.

https://www.who-umc.org/about-us/who-we-are/
 
PROFORMA
Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa. PROFORMA project is funded by European Union’s Framework Programme for Research and Innovation Horizon 2020 via the European and Developing Countries Clinical Trials Partnership Association (EDCTP2).

https://proforma.ki.se/
 
SPaRCS
SPaRCS aims to strengthen pharmacovigilance (PV) systems and clinical trials oversight of National Regulatory Authorities (NRAs) in Namibia, South Africa, Eswatini and Zimbabwe